Abstract

Clonal hematopoiesis (CH) is described as the outsized contribution of expanded clones of hematopoietic stem and progenitor cells (HSPCs) to blood cell production. The prevalence of CH increases dramatically with age. CH can be caused by somatic mutations in individual genes or by gains and/or losses of larger chromosomal segments. CH is a premalignant state; the somatic mutations detected in CH are the initiating mutations for hematologic malignancies, and CH is a strong predictor of the development of blood cancers. Moreover, CH is associated with nonmalignant disorders and increased overall mortality. The somatic mutations that drive clonal expansion of HSPCs can alter the function of terminally differentiated blood cells, including the release of elevated levels of inflammatory cytokines. These cytokines may then contribute to a broad range of inflammatory disorders that increase in prevalence with age. Specific somatic mutations in the peripheral blood in coordination with blood count parameters can powerfully predict the development of hematologic malignancies and overall mortality in CH. In this review, we summarize the current understanding of CH nosology and origins. We provide an overview of available tools for risk stratification and discuss management strategies for patients with CH presenting to hematology clinics.

1.
Martincorena
I
,
Raine
KM
,
Gerstung
M
, et al
.
Universal patterns of selection in cancer and somatic tissues
.
Cell
.
2017
;
171
(
5
):
1029
-
1041.e21
.
2.
Rozhok
AI
,
DeGregori
J
.
Toward an evolutionary model of cancer: considering the mechanisms that govern the fate of somatic mutations
.
Proc Natl Acad Sci U S A
.
2015
;
112
(
29
):
8914
-
8921
.
3.
Kakiuchi
N
,
Ogawa
S
.
Clonal expansion in non-cancer tissues
.
Nat Rev Cancer
.
2021
;
21
(
4
):
239
-
256
.
4.
Jaiswal
S
,
Fontanillas
P
,
Flannick
J
, et al
.
Age-related clonal hematopoiesis associated with adverse outcomes
.
N Engl J Med
.
2014
;
371
(
26
):
2488
-
2498
.
5.
Genovese
G
,
Kähler
AK
,
Handsaker
RE
, et al
.
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
.
N Engl J Med
.
2014
;
371
(
26
):
2477
-
2487
.
6.
McKerrell
T
,
Park
N
,
Moreno
T
, et al
.
Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis
.
Cell Rep
.
2015
;
10
(
8
):
1239
-
1245
.
7.
Beutler
E
,
Yeh
M
,
Fairbanks
VF
.
The normal human female as a mosaic of X-chromosome activity: studies using the gene for G-6-PD-deficiency as a marker ∗
.
Proc Natl Acad Sci U S A
.
1962
;
48
(
1
):
9
-
16
.
8.
Fey
MF
,
Liechti-Gallati
S
,
von Rohr
A
, et al
.
Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27 beta DNA probe
.
Blood
.
1994
;
83
(
4
):
931
-
938
.
9.
Fialkow
PJ
,
Gartler
SM
,
Yoshida
A
.
Clonal origin of chronic myelocytic leukemia in man
.
Proc Natl Acad Sci U S A
.
1967
;
58
(
4
):
1468
-
1471
.
10.
Steensma
DP
,
Bejar
R
,
Jaiswal
S
, et al
.
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
.
Blood
.
2015
;
126
(
1
):
9
-
16
.
11.
Desai
P
,
Mencia-Trinchant
N
,
Savenkov
O
, et al
.
Somatic mutations precede acute myeloid leukemia years before diagnosis
.
Nat Med
.
2018
;
24
(
7
):
1015
-
1023
.
12.
Niroula
A
,
Sekar
A
,
Murakami
MA
, et al
.
Distinction of lymphoid and myeloid clonal hematopoiesis
.
Nat Med
.
2021
;
27
(
11
):
1921
-
1927
.
13.
Abelson
S
,
Collord
G
,
Ng
SWK
, et al
.
Prediction of acute myeloid leukaemia risk in healthy individuals
.
Nature
.
2018
;
559
(
7714
):
400
-
404
.
14.
Jaiswal
S
,
Natarajan
P
,
Silver
AJ
, et al
.
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
.
N Engl J Med
.
2017
;
377
(
2
):
111
-
121
.
15.
Xie
M
,
Lu
C
,
Wang
J
, et al
.
Age-related mutations associated with clonal hematopoietic expansion and malignancies
.
Nat Med
.
2014
;
20
(
12
):
1472
-
1478
.
16.
Khoury
JD
,
Solary
E
,
Abla
O
, et al
.
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms
.
Leukemia
.
2022
;
36
(
7
):
1703
-
1719
.
17.
Arber
DA
,
Orazi
A
,
Hasserjian
RP
, et al
.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: integrating morphological, clinical, and genomic data
.
Blood
.
2022
;
140
(
11
):
1200
-
1228
.
18.
Sperling
AS
,
Gibson
CJ
,
Ebert
BL
.
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
.
Nat Rev Cancer
.
2017
;
17
(
1
):
5
-
19
.
19.
Laurie
CC
,
Laurie
CA
,
Rice
K
, et al
.
Detectable clonal mosaicism from birth to old age and its relationship to cancer
.
Nat Genet
.
2012
;
44
(
6
):
642
-
650
.
20.
Jacobs
KB
,
Yeager
M
,
Zhou
W
, et al
.
Detectable clonal mosaicism and its relationship to aging and cancer
.
Nat Genet
.
2012
;
44
(
6
):
651
-
658
.
21.
Gao
T
,
Ptashkin
R
,
Bolton
KL
, et al
.
Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis
.
Nat Commun
.
2021
;
12
(
1
):
338
.
22.
Loh
PR
,
Genovese
G
,
Handsaker
RE
, et al
.
Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations
.
Nature
.
2018
;
559
(
7714
):
350
-
355
.
23.
Loh
PR
,
Genovese
G
,
McCarroll
SA
.
Monogenic and polygenic inheritance become instruments for clonal selection
.
Nature
.
2020
;
584
(
7819
):
136
-
141
.
24.
Terao
C
,
Suzuki
A
,
Momozawa
Y
, et al
.
Chromosomal alterations among age-related haematopoietic clones in Japan
.
Nature
.
2020
;
584
(
7819
):
130
-
135
.
25.
Takahashi
K
,
Wang
F
,
Kantarjian
H
, et al
.
Copy number alterations detected as clonal hematopoiesis of indeterminate potential
.
Blood Adv
.
2017
;
1
(
15
):
1031
-
1036
.
26.
Papaemmanuil
E
,
Gerstung
M
,
Malcovati
L
, et al
.
Clinical and biological implications of driver mutations in myelodysplastic syndromes
.
Blood
.
2013
;
122
(
22
):
3616
-
3627
. quiz 3699.
27.
Papaemmanuil
E
,
Gerstung
M
,
Bullinger
L
, et al
.
Genomic classification and prognosis in acute myeloid leukemia
.
N Engl J Med
.
2016
;
374
(
23
):
2209
-
2221
.
28.
Barrio
S
,
Shanafelt
TD
,
Ojha
J
, et al
.
Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome
.
Leukemia
.
2017
;
31
(
1
):
170
-
176
.
29.
Zink
F
,
Stacey
SN
,
Norddahl
GL
, et al
.
Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly
.
Blood
.
2017
;
130
(
6
):
742
-
752
.
30.
Mitchell
E
,
Spencer Chapman
M
,
Williams
N
, et al
.
Clonal dynamics of haematopoiesis across the human lifespan
.
Nature
.
2022
;
606
(
7913
):
343
-
350
.
31.
Sun
D
,
Luo
M
,
Jeong
M
, et al
.
Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal
.
Cell Stem Cell
.
2014
;
14
(
5
):
673
-
688
.
32.
Schroeder
T
.
Hematopoietic stem cell heterogeneity: subtypes, not unpredictable behavior
.
Cell Stem Cell
.
2010
;
6
(
3
):
203
-
207
.
33.
Fabre
MA
,
de Almeida
JG
,
Fiorillo
E
, et al
.
The longitudinal dynamics and natural history of clonal haematopoiesis
.
Nature
.
2022
;
606
(
7913
):
335
-
342
.
34.
Yan
B
,
Ban
K
,
Chng
WJ
,
McCarroll
SA
.
Clonal hematopoiesis and blood-cancer risk
.
N Engl J Med
.
2015
;
372
(
11
):
1071
-
1072
.
35.
Holstege
H
,
Pfeiffer
W
,
Sie
D
, et al
.
Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis
.
Genome Res
.
2014
;
24
(
5
):
733
-
742
.
36.
Young
AL
,
Challen
GA
,
Birmann
BM
,
Druley
TE
.
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
.
Nat Commun
.
2016
;
7
:
12484
.
37.
Spira
A
,
Yurgelun
MB
,
Alexandrov
L
, et al
.
Precancer atlas to drive precision prevention trials
.
Cancer Res
.
2017
;
77
(
7
):
1510
-
1541
.
38.
Van Egeren
D
,
Escabi
J
,
Nguyen
M
, et al
.
Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms
.
Cell Stem Cell
.
2021
;
28
(
3
):
514
-
523.e9
.
39.
Lee-Six
H
,
Øbro
NF
,
Shepherd
MS
, et al
.
Population dynamics of normal human blood inferred from somatic mutations
.
Nature
.
2018
;
561
(
7724
):
473
-
478
.
40.
Williams
N
,
Lee
J
,
Mitchell
E
, et al
.
Life histories of myeloproliferative neoplasms inferred from phylogenies
.
Nature
.
2022
;
602
(
7895
):
162
-
168
.
41.
Welch
JS
,
Ley
TJ
,
Link
DC
, et al
.
The origin and evolution of mutations in acute myeloid leukemia
.
Cell
.
2012
;
150
(
2
):
264
-
278
.
42.
Weinstock
JS
,
Gopakumar
J
,
Burugula
BB
, et al
.
Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis
.
Nature
.
2023
;
616
(
7958
):
755
-
763
.
43.
Uddin
MM
,
Zhou
Y
,
Bick
AG
, et al
.
Longitudinal profiling of clonal hematopoiesis provides insight into clonal dynamics
.
Immun Ageing
.
2022
;
19
(
1
):
23
.
44.
Robertson
NA
,
Latorre-Crespo
E
,
Terradas-Terradas
M
, et al
.
Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects
.
Nat Med
.
2022
;
28
(
7
):
1439
-
1446
.
45.
Sperling
AS
,
Guerra
VA
,
Kennedy
JA
, et al
.
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
.
Blood
.
2022
;
140
(
16
):
1753
-
1763
.
46.
Hsu
JI
,
Dayaram
T
,
Tovy
A
, et al
.
PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy
.
Cell Stem Cell
.
2018
;
23
(
5
):
700
-
713.e6
.
47.
Wong
TN
,
Ramsingh
G
,
Young
AL
, et al
.
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
.
Nature
.
2015
;
518
(
7540
):
552
-
555
.
48.
Berger
G
,
Kroeze
LI
,
Koorenhof-Scheele
TN
, et al
.
Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT
.
Blood
.
2018
;
131
(
16
):
1846
-
1857
.
49.
Bolton
KL
,
Ptashkin
RN
,
Gao
T
, et al
.
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
.
Nat Genet
.
2020
;
52
(
11
):
1219
-
1226
.
50.
Coombs
CC
,
Zehir
A
,
Devlin
SM
, et al
.
Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes
.
Cell Stem Cell
.
2017
;
21
(
3
):
374
-
382.e4
.
51.
Wong
TN
,
Miller
CA
,
Jotte
MRM
, et al
.
Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential
.
Nat Commun
.
2018
;
9
(
1
):
455
.
52.
Levin
MG
,
Nakao
T
,
Zekavat
SM
, et al
.
Genetics of smoking and risk of clonal hematopoiesis
.
Sci Rep
.
2022
;
12
(
1
):
7248
.
53.
Dawoud
AAZ
,
Tapper
WJ
,
Cross
NCP
.
Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking
.
Leukemia
.
2020
;
34
(
10
):
2660
-
2672
.
54.
van Zeventer
IA
,
de Graaf
AO
,
van der Klauw
MM
, et al
.
Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality
.
Blood Adv
.
2021
;
5
(
17
):
3266
-
3278
.
55.
Karantanos
T
,
Gondek
LP
,
Varadhan
R
, et al
.
Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
.
Br J Haematol
.
2021
;
193
(
6
):
1142
-
1150
.
56.
van Zeventer
IA
,
Salzbrunn
JB
,
de Graaf
AO
, et al
.
Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years
.
Blood Adv
.
2021
;
5
(
8
):
2115
-
2122
.
57.
Kamphuis
P
,
van Zeventer
IA
,
de Graaf
AO
, et al
.
Sex differences in the spectrum of clonal hematopoiesis
.
Hemasphere
.
2023
;
7
(
2
):
e832
-
e837
.
58.
Kar
SP
,
Quiros
PM
,
Gu
M
, et al
.
Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis
.
Nat Genet
.
2022
;
54
(
8
):
1155
-
1166
.
59.
King
KY
,
Goodell
MA
.
Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response
.
Nat Rev Immunol
.
2011
;
11
(
10
):
685
-
692
.
60.
Yoshizato
T
,
Dumitriu
B
,
Hosokawa
K
, et al
.
Somatic mutations and clonal hematopoiesis in aplastic anemia
.
N Engl J Med
.
2015
;
373
(
1
):
35
-
47
.
61.
Lane
AA
,
Odejide
O
,
Kopp
N
, et al
.
Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia
.
Leukemia
.
2013
;
27
(
4
):
968
-
971
.
62.
Kulasekararaj
AG
,
Jiang
J
,
Smith
AE
, et al
.
Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome
.
Blood
.
2014
;
124
(
17
):
2698
-
2704
.
63.
Lundgren
S
,
Keränen
MAI
,
Kankainen
M
, et al
.
Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia
.
Leukemia
.
2021
;
35
(
5
):
1365
-
1379
.
64.
Hormaechea-Agulla
D
,
Matatall
KA
,
Le
DT
, et al
.
Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling
.
Cell Stem Cell
.
2021
;
28
(
8
):
1428
-
1442.e6
.
65.
Meisel
M
,
Hinterleitner
R
,
Pacis
A
, et al
.
Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host
.
Nature
.
2018
;
557
(
7706
):
580
-
584
.
66.
Franceschi
C
,
Campisi
J
.
Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases
.
J Gerontol A Biol Sci Med Sci
.
2014
;
69
(
suppl 1
):
S4
-
9
.
67.
Ferrucci
L
,
Fabbri
E
.
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
.
Nat Rev Cardiol
.
2018
;
15
(
9
):
505
-
522
.
68.
Dharan
NJ
,
Yeh
P
,
Bloch
M
, et al
.
HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults
.
Nat Med
.
2021
;
27
(
6
):
1006
-
1011
.
69.
Bekele
DI
,
Patnaik
MM
.
Autoimmunity, clonal hematopoiesis, and myeloid neoplasms
.
Rheum Dis Clin North Am
.
2020
;
46
(
3
):
429
-
444
.
70.
Arends
CM
,
Weiss
M
,
Christen
F
, et al
.
Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis
.
Haematologica
.
2020
;
105
(
6
):
e264
-
e267
.
71.
Svensson
EC
,
Madar
A
,
Campbell
CD
, et al
.
TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial
.
JAMA Cardiol
.
2022
;
7
(
5
):
521
-
528
.
72.
Tsai
FD
,
Lindsley
RC
.
Clonal hematopoiesis in the inherited bone marrow failure syndromes
.
Blood
.
2020
;
136
(
14
):
1615
-
1622
.
73.
Kennedy
AL
,
Myers
KC
,
Bowman
J
, et al
.
Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome
.
Nat Commun
.
2021
;
12
(
1
):
1334
.
74.
Xia
J
,
Miller
CA
,
Baty
J
, et al
.
Somatic mutations and clonal hematopoiesis in congenital neutropenia
.
Blood
.
2018
;
131
(
4
):
408
-
416
.
75.
Perdigones
N
,
Perin
JC
,
Schiano
I
, et al
.
Clonal hematopoiesis in patients with dyskeratosis congenita
.
Am J Hematol
.
2016
;
91
(
12
):
1227
-
1233
.
76.
Maryoung
L
,
Yue
Y
,
Young
A
, et al
.
Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations
.
J Clin Invest
.
2017
;
127
(
3
):
982
-
986
.
77.
West
RR
,
Calvo
KR
,
Embree
LJ
, et al
.
ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome
.
Blood Adv
.
2022
;
6
(
3
):
793
-
807
.
78.
Kessler
MD
,
Damask
A
,
O'Keeffe
S
, et al
.
Common and rare variant associations with clonal haematopoiesis phenotypes
.
Nature
.
2022
;
612
(
7939
):
301
-
309
.
79.
Silver
AJ
,
Bick
AG
,
Savona
MR
.
Germline risk of clonal haematopoiesis
.
Nat Rev Genet
.
2021
;
22
(
9
):
603
-
617
.
80.
Zhou
W
,
Machiela
MJ
,
Freedman
ND
, et al
.
Mosaic loss of chromosome Y is associated with common variation near TCL1A
.
Nat Genet
.
2016
;
48
(
5
):
563
-
568
.
81.
Bick
AG
,
Weinstock
JS
,
Nandakumar
SK
, et al
.
Inherited causes of clonal haematopoiesis in 97,691 whole genomes
.
Nature
.
2020
;
586
(
7831
):
763
-
768
.
82.
Steensma
DP
.
Clinical consequences of clonal hematopoiesis of indeterminate potential
.
Blood Adv
.
2018
;
2
(
22
):
3404
-
3410
.
83.
Weeks
LD
,
Niroula
A
,
Neuberg
D
, et al
.
Prediction of risk for myeloid malignancy in clonal hematopoiesis
.
NEJM Evid
.
2023
;
2
(
5
). 10.1056/evidoa2200310.
84.
Malcovati
L
,
Gallì
A
,
Travaglino
E
, et al
.
Clinical significance of somatic mutation in unexplained blood cytopenia
.
Blood
.
2017
;
129
(
25
):
3371
-
3378
.
85.
Gallì
A
,
Todisco
G
,
Catamo
E
, et al
.
Relationship between clone metrics and clinical outcome in clonal cytopenia
.
Blood
.
2021
;
138
(
11
):
965
-
976
.
86.
Gu
M
,
Kovilakam
SC
,
Dunn
WG
, et al
.
Multiparameter prediction of myeloid neoplasia risk
.
Nat Genet
.
2023
;
55
(
9
):
1523
-
1530
.
87.
Buscarlet
M
,
Provost
S
,
Zada
YF
, et al
.
Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A
.
Blood
.
2018
;
132
(
3
):
277
-
280
.
88.
Gibson
CJ
,
Lindsley
RC
,
Tchekmedyian
V
, et al
.
Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma
.
J Clin Oncol
.
2017
;
35
(
14
):
1598
-
1605
.
89.
Mouhieddine
TH
,
Sperling
AS
,
Redd
R
, et al
.
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
.
Nat Commun
.
2020
;
11
(
1
):
2996
.
90.
Ortmann
CA
,
Dorsheimer
L
,
Abou-El-Ardat
K
, et al
.
Functional dominance of CHIP-mutated hematopoietic stem cells in patients undergoing autologous transplantation
.
Cell Rep
.
2019
;
27
(
7
):
2022
-
2028.e3
.
91.
Gondek
LP
,
Zheng
G
,
Ghiaur
G
, et al
.
Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation
.
Leukemia
.
2016
;
30
(
9
):
1916
-
1920
.
92.
Gibson
CJ
,
Kennedy
JA
,
Nikiforow
S
, et al
.
Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias
.
Blood
.
2017
;
130
(
1
):
91
-
94
.
93.
Gibson
CJ
,
Kim
HT
,
Zhao
L
, et al
.
Donor clonal hematopoiesis and recipient outcomes after transplantation
.
J Clin Oncol
.
2022
;
40
(
2
):
189
-
201
.
94.
Frick
M
,
Chan
W
,
Arends
CM
, et al
.
Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation
.
J Clin Oncol
.
2019
;
37
(
5
):
375
-
385
.
95.
Fuster
JJ
,
MacLauchlan
S
,
Zuriaga
MA
, et al
.
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
.
Science
.
2017
;
355
(
6327
):
842
-
847
.
96.
Bick
AG
,
Pirruccello
JP
,
Griffin
GK
, et al
.
Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis
.
Circulation
.
2020
;
141
(
2
):
124
-
131
.
97.
Fidler
TP
,
Xue
C
,
Yalcinkaya
M
, et al
.
The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis
.
Nature
.
2021
;
592
(
7853
):
296
-
301
.
98.
Sano
S
,
Wang
Y
,
Yura
Y
, et al
.
JAK2 (V617F) -mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure
.
JACC Basic Transl Sci
.
2019
;
4
(
6
):
684
-
697
.
99.
Sano
S
,
Horitani
K
,
Ogawa
H
, et al
.
Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality
.
Science
.
2022
;
377
(
6603
):
292
-
297
.
100.
Haitjema
S
,
Kofink
D
,
van Setten
J
, et al
.
Loss of Y chromosome in blood is associated with major cardiovascular events during follow-up in men after carotid endarterectomy
.
Circ Cardiovasc Genet
.
2017
;
10
(
4
):
e001544
.
101.
Yu
Z
,
Fidler
TP
,
Ruan
Y
, et al
.
Genetic modification of inflammation and clonal hematopoiesis-associated cardiovascular risk
.
J Clin Invest
.
2023
;
133
(
18
):
e168597
.
102.
Gumuser
ED
,
Schuermans
A
,
Cho
SMJ
, et al
.
Clonal hematopoiesis of indeterminate potential predicts adverse outcomes in patients with atherosclerotic cardiovascular disease
.
J Am Coll Cardiol
.
2023
;
81
(
20
):
1996
-
2009
.
103.
Dorsheimer
L
,
Assmus
B
,
Rasper
T
, et al
.
Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure
.
JAMA Cardiol
.
2019
;
4
(
1
):
25
-
33
.
104.
Wong
WJ
,
Emdin
C
,
Bick
AG
, et al
.
Clonal haematopoiesis and risk of chronic liver disease
.
Nature
.
2023
;
616
(
7958
):
747
-
754
.
105.
Vlasschaert
C
,
McNaughton
AJM
,
Chong
M
, et al
.
Association of clonal hematopoiesis of indeterminate potential with worse kidney function and anemia in two cohorts of patients with advanced chronic kidney disease
.
J Am Soc Nephrol
.
2022
;
33
(
5
):
985
-
995
.
106.
Kestenbaum
B
,
Bick
AG
,
Vlasschaert
C
, et al
.
Clonal hematopoiesis of indeterminate potential and kidney function decline in the general population
.
Am J Kidney Dis
.
2023
;
81
(
3
):
329
-
335
.
107.
Dawoud
AAZ
,
Gilbert
RD
,
Tapper
WJ
,
Cross
NCP
.
Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease
.
Leukemia
.
2022
;
36
(
2
):
507
-
515
.
108.
Agrawal
M
,
Niroula
A
,
Cunin
P
, et al
.
TET2-mutant clonal hematopoiesis and risk of gout
.
Blood
.
2022
;
140
(
10
):
1094
-
1103
.
109.
Miller
PG
,
Qiao
D
,
Rojas-Quintero
J
, et al
.
Association of clonal hematopoiesis with chronic obstructive pulmonary disease
.
Blood
.
2022
;
139
(
3
):
357
-
368
.
110.
Kim
PG
,
Niroula
A
,
Shkolnik
V
, et al
.
Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis
.
J Exp Med
.
2021
;
218
(
12
):
e20211872
.
111.
Weeks
LD
,
Marinac
CR
,
Redd
R
, et al
.
Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia
.
Blood
.
2022
;
139
(
8
):
1246
-
1250
.
112.
Fuster
JJ
,
Zuriaga
MA
,
Zorita
V
, et al
.
TET2-loss-of-function-driven clonal hematopoiesis exacerbates experimental insulin resistance in aging and obesity
.
Cell Rep
.
2020
;
33
(
4
):
108326
.
113.
Anderson
LA
,
Pfeiffer
RM
,
Landgren
O
,
Gadalla
S
,
Berndt
SI
,
Engels
EA
.
Risks of myeloid malignancies in patients with autoimmune conditions
.
Br J Cancer
.
2009
;
100
(
5
):
822
-
828
.
114.
Fu
Y
,
Wu
W
,
Chen
Z
,
Gu
L
,
Wang
X
,
Ye
S
.
Trisomy 8 associated clonal cytopenia featured with acquired auto-inflammation and its response to JAK inhibitors
.
Front Med (Lausanne)
.
2022
;
9
:
895965
.
115.
Zhao
L-P
,
Boy
M
,
Azoulay
C
, et al
.
Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease
.
Leukemia
.
2021
;
35
(
9
):
2720
-
2724
.
116.
Savola
P
,
Lundgren
S
,
Keränen
MAI
, et al
.
Clonal hematopoiesis in patients with rheumatoid arthritis
.
Blood Cancer J
.
2018
;
8
(
8
):
69
.
117.
Beck
DB
,
Ferrada
MA
,
Sikora
KA
, et al
.
Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease
.
N Engl J Med
.
2020
;
383
(
27
):
2628
-
2638
.
118.
Obiorah
IE
,
Patel
BA
,
Groarke
EM
, et al
.
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1
.
Blood Adv
.
2021
;
5
(
16
):
3203
-
3215
.
119.
Gutierrez-Rodrigues
F
,
Kusne
Y
,
Fernandez
J
, et al
.
Spectrum of clonal hematopoiesis in VEXAS syndrome
.
Blood
.
2023
;
142
(
3
):
244
-
259
.
120.
Koskela
HLM
,
Eldfors
S
,
Ellonen
P
, et al
.
Somatic STAT3 mutations in large granular lymphocytic leukemia
.
N Engl J Med
.
2012
;
366
(
20
):
1905
-
1913
.
121.
Zekavat
SM
,
Lin
SH
,
Bick
AG
, et al
.
Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection
.
Nat Med
.
2021
;
27
(
6
):
1012
-
1024
.
122.
Shanafelt
TD
,
Kay
NE
,
Parikh
SA
, et al
.
Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL)
.
Leukemia
.
2021
;
35
(
1
):
239
-
244
.
123.
Shadman
M
.
Diagnosis and treatment of chronic lymphocytic leukemia: a review
.
JAMA
.
2023
;
329
(
11
):
918
-
932
.
124.
Bolton
KL
,
Koh
Y
,
Foote
MB
, et al
.
Clonal hematopoiesis is associated with risk of severe COVID-19
.
Nat Commun
.
2021
;
12
(
1
):
5975
.
125.
Bouzid
H
,
Belk
JA
,
Jan
M
, et al
.
Clonal hematopoiesis is associated with protection from Alzheimer’s disease
.
Nat Med
.
2023
;
29
(
7
):
1662
-
1670
.
126.
Steensma
DP
,
Bolton
KL
.
What to tell your patient with clonal hematopoiesis and why: insights from 2 specialized clinics
.
Blood
.
2020
;
136
(
14
):
1623
-
1631
.
127.
Bolton
KL
,
Zehir
A
,
Ptashkin
RN
, et al
.
The clinical management of clonal hematopoiesis: creation of a clonal hematopoiesis clinic
.
Hematol Oncol Clin North Am
.
2020
;
34
(
2
):
357
-
367
.
128.
Haring
B
,
Reiner
AP
,
Liu
J
, et al
.
Healthy lifestyle and clonal hematopoiesis of indeterminate potential: results from the Women's Health Initiative
.
J Am Heart Assoc
.
2021
;
10
(
5
):
e018789
.
You do not currently have access to this content.
Sign in via your Institution